Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BCL2 and ITPR1 B-cell CLL/lymphoma 2 inositol 1,4,5-trisphosphate receptor, type 1
  • Activation of BAD and translocation to mitochondria
  • Inflammasomes
  • The NLRP1 inflammasome
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Programmed Cell Death
  • Activation of BH3-only proteins
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Innate Immune System
  • Intrinsic Pathway for Apoptosis
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Integration of energy metabolism
  • cGMP effects
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Effects of PIP2 hydrolysis
  • Platelet calcium homeostasis
  • DAP12 signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Role of phospholipids in phagocytosis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Signaling by PDGF
  • DAP12 interactions
  • Opioid Signalling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • G alpha (q) signalling events
  • Signaling by EGFR
  • GPCR downstream signaling
  • Platelet homeostasis
  • Signaling by VEGF
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • G alpha (q) signalling events
  • DAG and IP3 signaling
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated cell proliferation
  • Downstream signaling of activated FGFR
  • Nitric oxide stimulates guanylate cyclase
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Signalling by NGF
  • PLC beta mediated events
  • Regulation of insulin secretion
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • Ca2+ pathway
  • Elevation of cytosolic Ca2+ levels
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Ibuprofen
  • Paclitaxel
  • Docetaxel
  • Rasagiline
BCL2 and HRAS B-cell CLL/lymphoma 2 Harvey rat sarcoma viral oncogene homolog
  • Activation of BAD and translocation to mitochondria
  • Inflammasomes
  • The NLRP1 inflammasome
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Programmed Cell Death
  • Activation of BH3-only proteins
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Innate Immune System
  • Intrinsic Pathway for Apoptosis
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • EPH-Ephrin signaling
  • SOS-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Signaling by FGFR mutants
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-2 signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Adaptive Immune System
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Post NMDA receptor activation events
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • IRS-related events
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • SHC1 events in EGFR signaling
  • RAF activation
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Activation of RAS in B cells
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by EGFRvIII
  • Ibuprofen
  • Paclitaxel
  • Docetaxel
  • Rasagiline
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5\'-Triphosphate
  • Guanosine-5\'-Diphosphate
  • N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
BCL2 and KRAS B-cell CLL/lymphoma 2 Kirsten rat sarcoma viral oncogene homolog
  • Activation of BAD and translocation to mitochondria
  • Inflammasomes
  • The NLRP1 inflammasome
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Programmed Cell Death
  • Activation of BH3-only proteins
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Innate Immune System
  • Intrinsic Pathway for Apoptosis
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Signalling to RAS
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Adaptive Immune System
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • Activation of RAS in B cells
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Constitutive Signaling by EGFRvIII
  • Ibuprofen
  • Paclitaxel
  • Docetaxel
  • Rasagiline
BCL2 and NRAS B-cell CLL/lymphoma 2 neuroblastoma RAS viral (v-ras) oncogene homolog
  • Activation of BAD and translocation to mitochondria
  • Inflammasomes
  • The NLRP1 inflammasome
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Programmed Cell Death
  • Activation of BH3-only proteins
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Innate Immune System
  • Intrinsic Pathway for Apoptosis
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Downstream signal transduction
  • Signalling to RAS
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Frs2-mediated activation
  • Signaling by Leptin
  • Adaptive Immune System
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • VEGFR2 mediated cell proliferation
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • Cytokine Signaling in Immune system
  • IRS-related events
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • RAF activation
  • SHC1 events in EGFR signaling
  • IRS-mediated signalling
  • Activation of RAS in B cells
  • FRS2-mediated cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Constitutive Signaling by EGFRvIII
  • Ibuprofen
  • Paclitaxel
  • Docetaxel
  • Rasagiline
BCL9 and PYGO2 B-cell CLL/lymphoma 9 pygopus family PHD finger 2
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
BCL9 and CTNNB1 B-cell CLL/lymphoma 9 catenin (cadherin-associated protein), beta 1, 88kDa
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
BRCA1 and NRIP1 breast cancer 1, early onset nuclear receptor interacting protein 1
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
BRCA1 and ESR1 breast cancer 1, early onset estrogen receptor 1
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Nuclear signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB4
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated Estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone
  • Estrone
  • Tamoxifen
  • Estradiol
  • Ethynodiol Diacetate
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Allylestrenol
  • Genistein
  • Compound 19
  • Compound 18
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estropipate
  • Quinestrol
  • Ospemifene
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
BRCA1 and ETV5 breast cancer 1, early onset ets variant 5
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
BRCA1 and TRRAP breast cancer 1, early onset transformation/transcription domain-associated protein
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Chromatin modifying enzymes
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • HATs acetylate histones
BRCA1 and MAP3K1 breast cancer 1, early onset mitogen-activated protein kinase kinase kinase 1, E3 ubiquitin protein ligase
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activated TLR4 signalling
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Toll-Like Receptors Cascades
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 10 (TLR10) Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • MyD88 dependent cascade initiated on endosome
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
BRCA1 and HIST1H2AB breast cancer 1, early onset histone cluster 1, H2ab
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Mitotic Prophase
  • Regulatory RNA pathways
  • RNA Polymerase I Promoter Clearance
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Cellular Senescence
  • Signaling by Wnt
  • HATs acetylate histones
  • M Phase
  • Amyloids
  • NoRC negatively regulates rRNA expression
  • Packaging Of Telomere Ends
  • Telomere Maintenance
  • Nucleosome assembly
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • DNA methylation
  • Transcriptional regulation by small RNAs
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Chromosome Maintenance
  • HDACs deacetylate histones
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • RNA Polymerase I Transcription
  • formation of the beta-catenin:TCF transactivating complex
  • Meiotic synapsis
  • Epigenetic regulation of gene expression
  • Senescence-Associated Secretory Phenotype (SASP)
  • Negative epigenetic regulation of rRNA expression
  • PRC2 methylates histones and DNA
  • Cell Cycle, Mitotic
  • RMTs methylate histone arginines
  • Chromatin modifying enzymes
  • Oxidative Stress Induced Senescence
  • TCF dependent signaling in response to WNT
  • RNA Polymerase I Promoter Opening
  • SIRT1 negatively regulates rRNA Expression
  • Signaling by WNT in cancer
  • Condensation of Prophase Chromosomes
BRCA1 and HIST2H2AC breast cancer 1, early onset histone cluster 2, H2ac
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Mitotic Prophase
  • Regulatory RNA pathways
  • RNA Polymerase I Promoter Clearance
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Cellular Senescence
  • Signaling by Wnt
  • HATs acetylate histones
  • M Phase
  • Amyloids
  • NoRC negatively regulates rRNA expression
  • Packaging Of Telomere Ends
  • Telomere Maintenance
  • Nucleosome assembly
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • DNA methylation
  • Transcriptional regulation by small RNAs
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Chromosome Maintenance
  • HDACs deacetylate histones
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • RNA Polymerase I Transcription
  • formation of the beta-catenin:TCF transactivating complex
  • Meiotic synapsis
  • Epigenetic regulation of gene expression
  • Senescence-Associated Secretory Phenotype (SASP)
  • Negative epigenetic regulation of rRNA expression
  • PRC2 methylates histones and DNA
  • Cell Cycle, Mitotic
  • RMTs methylate histone arginines
  • Chromatin modifying enzymes
  • Oxidative Stress Induced Senescence
  • TCF dependent signaling in response to WNT
  • RNA Polymerase I Promoter Opening
  • SIRT1 negatively regulates rRNA Expression
  • Signaling by WNT in cancer
  • Condensation of Prophase Chromosomes
BRCA1 and FAM175A breast cancer 1, early onset family with sequence similarity 175, member A
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
BRCA1 and MLH1 breast cancer 1, early onset mutL homolog 1
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Meiotic recombination
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch Repair
BRCA1 and NCOA2 breast cancer 1, early onset nuclear receptor coactivator 2
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • PPARA activates gene expression
  • Bile acid and bile salt metabolism
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Organelle biogenesis and maintenance
  • Metabolism of lipids and lipoproteins
  • Metabolic disorders of biological oxidation enzymes
  • Phase 1 - Functionalization of compounds
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Generic Transcription Pathway
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Cytochrome P450 - arranged by substrate type
  • Endogenous sterols
  • Transcriptional regulation of white adipocyte differentiation
  • Biological oxidations
  • Synthesis of bile acids and bile salts
  • Orphan transporters
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • Recycling of bile acids and salts
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • REV-ERBA represses gene expression
  • Defective CYP1B1 causes Glaucoma
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Mitochondrial biogenesis
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Synthesis of bile acids and bile salts via 27-hydroxycholesterol
  • Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Transcriptional activation of mitochondrial biogenesis
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
BRCA1 and KAT5 breast cancer 1, early onset K(lysine) acetyltransferase 5
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Chromatin modifying enzymes
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • formation of the beta-catenin:TCF transactivating complex
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by Wnt
  • Signaling by WNT in cancer
  • HATs acetylate histones
BRCA1 and MSH2 breast cancer 1, early onset mutS homolog 2
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch Repair
BRCA1 and MSH3 breast cancer 1, early onset mutS homolog 3
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • Mismatch Repair
BRCA1 and CEP57L1 breast cancer 1, early onset centrosomal protein 57kDa-like 1
  • ATM mediated phosphorylation of repair proteins
  • Meiotic recombination
  • Fanconi Anemia pathway
  • ATM mediated response to DNA double-strand break
  • Homologous Recombination Repair
  • Meiotic synapsis
  • Homologous recombination repair of replication-independent double-strand breaks
  • Recruitment of repair and signaling proteins to double-strand breaks
  • Double-Strand Break Repair

Page 16 out of 1171 pages